AAA+ proteases: the first line of defense against mitochondrial damage

Gautam Pareek
Cell and Molecular Biology, St. Jude Children’s Research Hosp, Memphis, TN, USA

ABSTRACT

Mitochondria play essential cellular roles in Adenosine triphosphate (ATP) synthesis, calcium homeostasis, and metabolism, but these vital processes have potentially deadly side effects. The production of the reactive oxygen species (ROS) and the aggregation of misfolded mitochondrial proteins can lead to severe mitochondrial damage and even cell death. The accumulation of mitochondrial damage is strongly implicated in aging and several incurable diseases, including neurodegenerative disorders and cancer. To oppose this, metazoans utilize a variety of quality control strategies, including the degradation of the damaged mitochondrial proteins by the mitochondrial-resident proteases of the ATPase Associated with the diverse cellular Activities (AAA+) family. This mini-review focuses on the quality control mediated by the mitochondrial-resident proteases of the AAA+ family used to combat the accumulation of damaged mitochondria and on how the failure of this mitochondrial quality control contributes to diseases.

Subjects Biochemistry, Molecular Biology, Neuroscience
Keywords AAA+ Protease, Mitochondrial quality control, Mitochondria in neurological disorders, Mitochondrial Unfolded Protein Response, Mitochondrial Translation

RATIONALE: THE CONUNDRUM OF THE DAMAGED MITOCHONDRIA AND THE ROLE OF THE SURVEILLANCE PATHWAYS

Mitochondria are indispensable for cellular life and perform a plethora of functions, including calcium homeostasis, regulation of programmed cell death, regulation of innate immunity, and stem cell fate (Nunnari & Suomalainen, 2012; Bock & Tait, 2020; McBride, Neuspiel & Wasiak, 2006; Kauppila, Kauppila & Larsson, 2017; Chandel, 2015; Vasan, Werner & Chandel, 2020). Most important of all, mitochondria produce almost all the vital cellular energy in the form of Adenosine triphosphate (ATP) by virtue of the different respiratory chain (RC) complexes embedded in the inner mitochondrial membrane (Milenkovic et al., 2017; Gustafsson, Falkenberg & Larsson, 2016; Sousa, D’Imprima & Vonck, 2018; Zhao et al., 2019). These RC complexes are involved in coupling the mitochondrial membrane potential created by the proton gradient to the synthesis of ATP. However, mitochondria face a quality control challenge during their lifetime. In addition to producing ATP, these RC complexes, mainly complexes I and III, produce a large amount of reactive oxygen species (ROS) by electron leakage, which results in the partial reduction of oxygen to form the detrimental superoxide radicals (Quinlan et al., 2013; Murphy, 2009). The excessive ROS produced by this process presents a quality control
(QC) challenge for the mitochondria and the cell. The dual genetic origin of the mitochondria also poses a challenge to its homeostasis. Mitochondria harbor their own small circular DNA, which encodes for 37 genes, including 13 proteins of the RC complexes, 22 tRNAs, and two rRNAs of mitochondrial ribosomes in the human (Hällberg & Larsson, 2014). The vast majority of the remaining more than 1,000 mitochondrial proteins are encoded by the nuclear genome and are imported into the mitochondria by the translocase of the outer membrane ‘TOM’ and translocase of the inner membrane ‘TIM’ complex (Pfanner, Warscheid & Wiedemann, 2019; Neupert & Herrmann, 2007). Therefore, mitochondrial biogenesis, specifically the RC complexes’ biogenesis, heavily relies on the coordinated expression of the nuclear and mitochondrially encoded subunits. Any perturbation in this equilibrium can lead to the accumulation of protein aggregates and eventually an adverse effect on mitochondria and the cellular health (Youle, 2019).

Thankfully, to combat the damage and the occurrence of ROS and misfolded protein aggregates, mitochondria have evolved a variety of surveillance pathways that are activated upon the trigger of the stress (Rugarli & Langer, 2012; Pickles, Vigié & Youle, 2018; Roca-Portoles & Tait, 2021; Quiles & Gustafsson, 2020). The most studied pathway of all is the ‘mitophagy’ pathway which involves the degradation of the whole mitochondria in the lysosome through a mitochondrial selective form of autophagy in extreme stress conditions (Narendra, Walker & Youle, 2012; Whitworth & Pallanck, 2017). In yeast, the mitophagy pathway is carried out by the ‘Atg32’ protein, which binds to an adaptor ‘Atg11’, and then mitochondria are recruited to and imported into the vacuole for degradation and recycling of its contents (Kanki et al., 2009). However, metazoans possess entirely different machinery for mitophagy, including the kinase ‘Pink1’ and the ubiquitin ligase ‘Parkin’ and several other adaptors, including P62, Optineurin, Nuclear dot protein 52 (NDP52), Human T-Cell Leukemia Virus Type 1 Binding Protein 1 (TAX1BP1) and Neighbor of BRCA1 gene 1 (NBR1) (Narendra et al., 2008; Narendra et al., 2010; Jin et al., 2010; Lazarou et al., 2015; Martin, Dawson & Dawson, 2011). Interestingly, the mutations in the genes of the mitophagy pathway, including Pink1 and Parkin, have been shown to cause Parkinson’s disease in humans and genetic disruption of these genes causes locomotor and behavioral deficits and accumulation of dysfunctional mitochondria in a variety of model organisms (Greene et al., 2003; Scarffe et al., 2014; Clark et al., 2006; Park et al., 2006; Itier et al., 2003; Lee et al., 2017; Shin et al., 2011; Yang et al., 2006).

The mechanistic details of this pathway have been discussed in pioneering reviews in the past and are out of scope for this review article (Pickles, Vigié & Youle, 2018; Whitworth & Pallanck, 2017; Ge, Dawson & Dawson, 2020).

The Mitochondrial network is dynamic; mitochondria merge by ‘fusion’ and separate from each other by ‘fission’ (Chen & Chan, 2017; Friedman et al., 2011; Youle & van der Bliek, 2012). The mitochondrial ‘fusion’ allows mitochondria to exchange their content and promotes functional complementation in the event of mitochondrial damage. In contrast, mitochondrial ‘fission’ facilitates the segregation of damaged mitochondria and subsequent removal by mitophagy. These processes are crucial to mitochondrial proteostasis since mutations in the components of the fission/fusion machinery have been shown to cause neurodegenerative diseases in humans, including Charcot-Marie-Tooth
Type 2A (CMT2A), peripheral neuropathy, and Dominant Optic Atrophy (DOA) (Chan, 2020).

The contribution of ‘mitophagy’ and ‘mitochondrial dynamics’ to mitochondrial quality control is indisputable. However, recent reports have demonstrated that these pathways cannot account for the total mitochondrial protein turnover in the cell (Vincow et al., 2013; Vincow et al., 2019). The quantitative proteomic studies performed in fruit flies and Drosophila S2 cells have demonstrated that the half-lives of different ribosomal proteins lie very close to each other, in agreement with the fact that the whole ribosomes are turned over as a single unit by the ‘ribophagy’ pathway. However, in the same study, mitochondrial proteins exhibited a wide range of half-lives that cannot be explained by a sole mitophagy-mediated mitochondrial protein degradation, suggesting more than one mechanism responsible for the turnover of mitochondria (Vincow et al., 2013). Subsequent studies showed that nearly 35% (one-third) of all mitochondrial protein turnover occurred through autophagy and almost 25% through the parkin-dependent mitophagy (Vincow et al., 2019). Additionally, utilizing mito-keima and mito-QC based reporter assays, it has been shown that the basal mitophagy flux is tissue-specific, and genetic disruption of the Pink1 or Parkin has a very modest effect on this flux (Lee et al., 2018; McWilliams et al., 2016; Sun et al., 2017). That being the case, the quality control mediated by the ATPase Associated with diverse cellular Activities (AAA+) serine proteases represent likely candidates to account for the majority of the mitochondrial protein turnover as they sense and degrade selective damaged mitochondrial components, henceforth, explaining the broad distribution of mitochondrial protein half-lives.

SCOPE AND SURVEY METHODOLOGY

The mitochondrial AAA+ proteases have gained significant attention and broader interest from the scientific community from different research areas due to their role in human health and diseases. To supplement the existing information as relevant literature about AAA+ proteases has increased in the past years, this perspective review discussed the classification, structural insights, functions, and recently reported substrates of the AAA+ proteases. The relevant pieces of literature on the topic were identified using databases like Pubmed, Google Scholar, Web of Science, and ScienceDirect. Briefly, the review identified 154 relevant research articles from research labs working on AAA+ proteases across the globe. To help move the field forward, this study presents a systematic review structured to discuss (1) the need for mitochondrial QC and how AAA+ proteases supplement this need, (2) the neurodegenerative diseases associated with the AAA+ proteases, (3) what have we learned from the disease model systems, and (4) substrates of the AAA+ proteases.

GENERAL OVERVIEW AND CLASSIFICATION OF THE AAA+ PROTEASE FAMILY

The FtsH (Filamentous temperature sensitive H)-related AAA+ proteases are present in all kingdoms of life, from bacteria to humans, and are classified into different families depending on their localization and domain organization (Sauer & Baker, 2011; Quirós, Langer & López-Otín, 2015). This family of proteases forms oligomeric complexes
that use energy from ATP hydrolysis to unfold and transport substrates to their zinc metalloprotease domain for degradation. These proteases are comprised of an axial pore formed by the oligomeric ring of the AAA+ ATPase domain. This pore size is narrow enough to block the passage of any folded protein toward an inner proteolytic chamber where proteolysis occurs (Sauer et al., 2004). Therefore, the energy derived from the cycles of ATP hydrolysis by the ATPase domain is utilized to induce the conformational changes in the substrate protein to unfold and transport substrates to the proteolytic cavity for degradation.

Higher eukaryotes, including humans, have five major nuclear DNA encoded AAA+ proteases in the mitochondria, distinguished by their subunit composition and localization (Fig. 1A). The i-AAA (commonly known as Yme1l1) and m-AAA proteases are localized in the inner membrane, and the Lon and Clp family of proteases are matrix-localized (Deshwal, Fiedler & Langer, 2020). Furthermore, the catalytic domains of the m-AAA and i-AAA proteases face the matrix and the intermembrane space, respectively, to protect against the insults on both sides of the inner membrane. The m-AAA protease is classified into two forms: hetero-oligomeric complexes of the paraplegin protein and the ATPase family gene 3-like 2 (Afg3l2) protein, and the homo-oligomeric complexes of the Afg3l2 protein. For all the AAA+ proteases, the ATPase and the proteolytic subunits are contained on a single polypeptide separated by a short linker region, except the Clp family, which is composed of the proteolytic (ClpP) and ATPase (ClpX) subunits present in the two different proteins (Fig. 1A).

Recent reports based on cryo-electron microscopy have provided unique structural insights into the Yme1l1, Afg3l2, and Lon protease (Puchades et al., 2017; Puchades et al., 2019; Shin et al., 2021). The quaternary organization of yeast Yme1l1 protease has revealed that the six AAA+ domains form an asymmetric spiral staircase on the top of a planar symmetric hexametric protease ring (Fig. 1B) (Puchades et al., 2017). Notably, four of the six subunits in Yme1l1 are in the ATP-bound form; the lowest subunit has the ADP-like density in the nucleotide-binding pocket, whereas the binding pocket of one of the subunits possesses an “apo-like” nucleotide-free state. The substrate engagement in the asymmetric ring is coordinated by the two conserved tyrosine residues forming a spiral staircase around the translocating substrate by intercalating into its backbone (Fig. 1B). The sequential ATP-hydrolysis around the ring results in subsequent substrate translocation to the proteolytic domain in a stepwise fashion. The cryo-EM structure of the human truncated Afg3l2 protein comprising the ATPase and protease domain has highlighted that the basic structural features and the fundamental mechanisms of ATP hydrolysis and substrate translocation are relatively conserved between the i-AAA and m-AAA family of proteases (Puchades et al., 2019). However, some unique evolutionary protein sequence adaptations related to their extreme C-terminus in i-AAA and m-AAA proteases enable them to process their distinct substrates in a different microenvironment. Surprisingly, the cryo-EM structure of the human Lon protease has revealed that the substrate binding alone to the AAA+ domain is not sufficient to produce allosteric transmission to the proteolytic domain and the activation of the proteolytic chamber was only achieved in the presence of peptidomimetic inhibitor ‘bortezomib’ suggesting an
additional level of regulation which requires the substrate-binding within the protease domain to induce the activated conformation of the domain (Shin et al., 2021).

The activity of all AAA+ proteases is under strict scrutiny to prevent the uncontrolled degradation of mitochondrial proteins. The precise mechanism by which the AAA+ proteases engage with their specific substrates lies in the binding to the particular sequences that serve as potential degron or degradation signals on the target protein (Glynn, 2017; Steele & Glynn, 2019; Leonhard et al., 2000). These degradation signals are usually highly hydrophobic and are 10–20 amino acids long (Gur & Sauer, 2008; Rampello & Glynn, 2017; Leonhard et al., 1999). The Yme1l1 protease recognizes its substrates...
through a specific motif of amino acids, including the F-h-h-F (F = phenylalanine and h stands for any hydrophobic residue) accessible for degradation in the unfolded state but hidden in a natively folded form of the protein (Shi, Rampello & Glynn, 2016). The accumulation of protected intermediates from experiments involving dihydrofolate reductase and stabilizing ligand methotrexate has demonstrated that the degradation of the target protein by Yme1l1 is achieved by processive unfolding and translocation to the proteolytic chamber from the degron terminus (Shi, Rampello & Glynn, 2016). Furthermore, a highly similar sequence (WRFAWFP) rich in aromatic amino acids from β-galactosidase has been identified as the primary recognition site for the Lon protease (Gur & Sauer, 2008). The human Lon protease has been shown to preferentially recognize and degrade the unfolded proteins harboring degron signals, including the folding incompetent form of the ornithine transcarbamylase (OTC) but not the aggregated form of the malate dehydrogenase (MDH) (Bezawork-Geleta et al., 2015). Moreover, The peptidase specificity profile of Afg3l2 has demonstrated that this protease discriminates its potential substrates by cleaving peptide bonds adjacent to either the hydrophobic (most commonly phenylalanine) or small polar residues in the P1’ position (the position adjacent to the scissile bond) (Ding et al., 2018). Overall, the recent structural details provide a molecular framework to understand the mechanics of the AAA+ protease machines and to appreciate their role in health and disease.

m-AAA proteases

The m-AAA proteases are embedded in the inner membrane with their active site oriented towards the matrix. There are two different versions of m-AAA; one is composed entirely of the homoligomers of the Afg3l2 protein; the other is a hetero-oligomeric complex of the Afg3l2 and Paraplegin proteins. The heterozygous missense mutations in the AFG3L2 gene cause spinocerebellar ataxia (SCA28) disease characterized by cerebellar dysfunction due to Purkinje cell degeneration (Fig. 1A) (Di Bella et al., 2010). Most of these mutations are clustered in the protease domain’s highly conserved region, and one of the mutations is present at the asparagine 432 positions in the ATPase domain. All these mutations result in the loss of the Afg3l2 activity and impair the degradation/maturation of its substrates. The homozygous missense mutation in AFG3L2 causes spastic ataxia neuropathy syndrome characterized by progressive lower limb spastic paraparesis, cerebellar atrophy, peripheral neuropathy, ptosis, dystonia, and progressive myoclonic epilepsy (Fig. 1A) (Pierson et al., 2011). This homozygous recessive mutation alters the conserved tyrosine at 616 positions to cysteine and impairs the homo- and hetero-oligomerization propensity of the Afg3l2 protein. The homozygous missense mutations in the SPG7 gene (encoding Paraplegin protease) cause the hereditary spastic paraplegia (HSP) disease characterized by the progressive weakness and spasticity of the lower limbs and by the loss of upper motor neurons of the corticospinal tracts (Fig. 1A) (Wilkinson et al., 2004). Additionally, compound heterozygous and heterozygous mutations in the SPG7 gene are also responsible for the progressive external ophthalmoplegia with early or progressive ataxia, dysphagia, and proximal myopathy (Pfeffer et al., 2014). A closer examination of these patients’ skeletal muscle biopsies revealed evidence of the mosaic respiratory chain
deficiency and an increase in mitochondrial biogenesis, giving rise to ‘ragged-blue’ fibers. These defects were accompanied by accelerated clonal expansion of mitochondrial DNA mutations and deletions along with increased mitochondrial mass and hyper-fused mitochondria in affected individuals. The deficiency of the yeast homolog of m-AAA protease Yta10/Yta12 is viable but causes a growth defect on a nutrient source containing glycerol that requires a mitochondrial respiration (Arlt et al., 1996). The homozygous knockout mice of AFG3L2 exhibited a defect in axonal development and myelination accompanied by early paraparesis and tetraparesis (Maltecca et al., 2008). These mice do not survive beyond day 16. The heterozygous AFG3L2 mouse recapitulated some pathological features of SCA28, including cerebellar atrophy, dark degeneration of Purkinje cells, and mitochondrial dysfunction (Maltecca et al., 2009). These findings suggest that haploinsufficiency is responsible for the ataxia disease associated with mutations in the AFG3L2 gene. The knockout of AFG3L2 in Drosophila is larval lethal, and RNAi-mediated knockdown causes shortened lifespan, locomotor deficits, and severe neurological and mitochondrial morphological abnormalities (Pareek & Pallanck, 2020). Paraplegin deficiency in various model organisms, including Drosophila and mouse, is viable. Still, adults exhibited severe phenotypes, including shortened lifespan, behavioral deficits, neurodegeneration, and accumulation of dysfunctional mitochondria along with the disorganized cristae network (Ferreirinha et al., 2004; Atorino et al., 2003; Pareek, Thomas & Pallanck, 2018). The paraplegin deficient mice exhibited mitochondrial morphological abnormalities in synaptic terminals and distal regions of axons followed by axonal swelling, degeneration, and behavioral abnormalities. The ultrastructural morphology of the photoreceptor terminals of the Drosophila paraplegin knockout displayed the progressive neurodegenerative phenotype, severely swollen and dysmorphic mitochondria accompanied by altered axonal transport of mitochondria. Despite co-assembling as a heteromeric complex, the spectrum of diseases caused by mutations in the Afg3l2 and paraplegin are distinct. The interplay between these proteins and their substrates in the mitochondria is poorly understood.

The m-AAA protease Afg3l2 plays a crucial role in regulating mitochondrial translation by participating in the maturation of one of the large mitochondrial ribosomal subunits, Mrpl32 (Nolden et al., 2005). The Mrpl32 maturation by Afg3l2 protease is conserved in yeast, flies, mice, and human cell lines (Pareek & Pallanck, 2020; Almajan et al., 2012). The defect in the processing led to the defective ribosome assembly and the attenuation of the mitochondrial translation (Fig. 2). This subsequently caused a defect in the RC complexes comprised of the subunits encoded by the mitochondrial DNA, including complex I, III, IV, and V (Pareek & Pallanck, 2020). An imbalance in the stoichiometry of nuclear vs. mitochondrial DNA encoded RC subunits caused the accumulation of protein aggregates and activation of the mitochondrial unfolded protein response (mito-UPR) (Fig. 2). Afg3l2 deficient worms (AFG3L2 has been confusingly referred to as SPG7 in worms) served as one of the first models to understand the mito-UPR (Nargund et al., 2012). The activation of the mito-UPR restores protein homeostasis utilizing a twopronged approach consisting of increased expression of chaperones and proteases to
facilitate the refolding/degradation of the misfolded proteins and phosphorylation-mediated inactivation of the cytosolic translation-initiation factor eIF2α by GCN2 kinase to attenuate cytoplasmic translation to reduce the burden on the mitochondrial protein folding machinery under stress conditions (Baker et al., 2012). However, some of these phenotypes, including the Mrpl32 maturation defect and activation of the mito-UPR, have not been observed in the Paraplegin deficient flies (Pareek & Pallanck, 2020). These recent findings suggest that the Afg3l2 homomers and the Afg3l2/Paraplegin heteromultimers have independent substrates. The result further supports this hypothesis that the SPG7 deficient flies did not exhibit defects in the activity or abundance of several RC complexes that contain subunits encoded by the mitochondrial genome and instead showed a defect in the complex II activity, which is encoded by the nuclear genome (Pareek, Thomas & Pallanck, 2018).

The mitochondria also play a crucial role in calcium buffering and have a calcium uniporter complex (MCU) to uptake calcium from the cytoplasm, thereby helping regulate

---

**Figure 2 The multitasking AAA+ protease family.** The mitochondrial AAA+ proteases regulate a diverse array of functions in the mitochondria, including the regulation of mitochondrial morphology, mitochondrial trafficking, glucose, fatty acids and lipid metabolism, mitochondrial calcium homeostasis, Fe/S cluster synthesis, mitochondrial transcription and translation, mitochondrial ribosome biogenesis, heme formation, innate immune response and degradation of misfolded protein aggregates. Full-size DOI: 10.7717/peerj.14350/fg-2
the cytoplasmic calcium levels (Baughman et al., 2011). Recent findings have reported that the \(m\)-AAA proteases degrade a regulatory subunit of the MCU complex, known as the Essential MCU REgulator (EMRE) (Sancak et al., 2013; König et al., 2016; Tsai et al., 2017). The formation of the constitutively active MCU-EMRE subcomplex in the absence of another regulatory subunit, Mitochondrial Calcium Uptake Protein 1 (MICU1), caused the calcium overload in the mitochondrial matrix and triggered the opening of the mitochondrial permeability transition pore (mPTP) and necrosis mediated cell death (Bernardi, 2013). However, the role of the \(m\)-AAA protease in the regulation of the MCU is disputed since the depletion of the MCU failed to rescue the behavioral defects, Purkinje cell degeneration, and the neuroinflammatory response of the Afg3l2 mutants (Patron, Sprenger & Langer, 2018). While in contrast to this, it has also been shown using cultured Purkinje cells derived from the cerebella of newborn mice that the depolarized mitochondria in Afg3l2-deficient cells are not efficient to buffer induced \(Ca^{2+}\) peaks, increasing the cytoplasmic \(Ca^{2+}\) concentrations, which subsequently triggers the dark cell degeneration (Maltecca et al., 2015). The calcium buffering is particularly critical for the Purkinje cells as they are comprised of the highly branched dendritic arbors receiving inputs from glutamatergic stimulation of various receptors, including ionotrophic \(\alpha\)-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and metabotropic receptors mGluR1 and, are therefore exposed to massive and sudden \(Ca^{2+}\) influx, making them susceptible to glutamate-mediated excitotoxicity. Notably, in the haploinsufficient Afg3l2 SCA28 mice, the partial genetic depletion of the metabotropic glutamate receptor mGluR1 or administration of the \(\beta\)-lactam antibiotic ceftriaxone, which promotes synaptic glutamate clearance, both decreased \(Ca^{2+}\) influx in Purkinje cells. It also improved the ataxic phenotype (Maltecca et al., 2015). More future work will be required to examine this matter in greater detail to determine how sensitive the mitochondrial calcium uptake is in response to the dosages of Afg3l2 protein.

The Afg3l2 protease control several other aspects of mitochondrial biology, including mitochondrial morphology, by regulating the processing of the inner mitochondrial membrane protein Opa1 (Fig. 2) (Ehses et al., 2009; Ishihara et al., 2006). The inner mitochondrial membrane fusion success depends on the balanced stoichiometry of the large and small isoforms of the Opa1 protein (Mishra et al., 2014). The deficiency of the Afg3l2 \(m\)-AAA protease caused the activation of another protease Oma1 (Ehses et al., 2009). The enhanced Oma1 activity led to the cleavage of the Opa1 long isoform to the shorter isoform and, subsequently, mitochondrial fragmentation. The Afg3l2 protease also cleaves mitophagy protein Pink1 inside the mitochondrial matrix, and the knockdown of the protease stabilizes the smaller form of Pink1 generated after the matrix processing peptidase (MPP) cleavage (Greene et al., 2012; Thomas et al., 2014). However, the stabilization of this cleavage product did not upregulate the downstream mitophagy pathway and did not affect the parkin recruitment to the mitochondria. Depleting the Afg3l2 protease in mouse primary cortical neurons drastically impaired the anterograde transport of the mitochondria, thereby depleting the synapses out of the mitochondria (Kondadi et al., 2014). The underlying cause of this defect has been attributed to the tau
hyperphosphorylation by kinases, including the protein kinase A (PKA) and ERK1/2, which were activated by high ROS caused by the depletion of the Afg3l2 protease.

**i-AAA protease**

The Yme1l1 is an ATP-dependent metalloprotease embedded in the inner mitochondrial membrane, with its protease domain facing the intermembrane space (referred to as i-AAA protease). The homozygous missense mutation in the *YME1L1* is associated with a multisystemic mitochondriopathy with neurological abnormalities, including intellectual disability, motor development and speech delay, and optic nerve atrophy with visual and hearing impairment (*Hartmann et al., 2016*). This mutation alters the highly conserved arginine at 149 positions within the predicted mitochondrial targeting sequence to the tryptophan. It abrogates the maturation of the Yme1l1 by MPP after the import into the mitochondria. The homozygous Yme1l1 knockout in *Drosophila* caused shortened lifespan, locomotor deficit, photoreceptor degeneration, and apoptosis-mediated cell death (*Qi et al., 2016*). These flies possessed mitochondria with disrupted cristae network, dysfunctional RC activity, and misfolded protein aggregates. The nervous system-specific knockout of *YME1L1* in mice caused microphthalmia, cataracts, progressive axonal degeneration of dorso-lateral tracts, and inflammation in the retina and spinal cords accompanied by locomotor impairment of hind limbs (*Sprenger et al., 2019*). These mice also manifested late onset RC dysfunction, loss of cristae structure, mitochondrial fragmentation, and a defect in the anterograde transport of the mitochondria.

The role of the Yme1l1 protease in regulating mitochondrial morphology is well established (Fig. 2). The Yme1l1, along with the Oma1 protease, holds a switch that dictates mitochondrial fusion/fragmentation in response to membrane depolarization and cellular bioenergetic status (*Rainbolt et al., 2016*). In conditions where membrane depolarization occurs in the presence of ATP, the Oma1 protease is degraded in a Yme1l1-dependent manner. These conditions stabilize the Opa1 short isoform generated by the Yme1l1 cleavage at the S2 site and favor mitochondrial fusion with enhanced RC activity, protection from mitophagy, and protection from apoptosis. However, when the depletion of ATP accompanies mitochondrial membrane depolarization, the Yme1l1 protease is degraded, and Oma1 is stabilized. The stabilization of Oma1 protease caused the cleavage of Opa1 at the S1 site and, subsequently, blockage in fusion, reduced RC activity, susceptibility to mitophagy, and apoptosis. Moreover, a recent study suggested that the Yme1l1 is part of the enormous protease complex formed by the Yme1l1-PARL proteases along with the scaffold protein Stomatin-like protein 2 (SLP2). This complex SLP2–PARL–YME1L1 not only regulates the Pink1 kinase and Pgam5 phosphatase processing but also inhibits the stress-activated Oma1 protease and promotes the cell survival (*Wai et al., 2016*).

The Yme1l1 protease also participates in the integrated stress signaling (ISR) pathway during stress conditions (Fig. 2). The Yme1l1 degrades the import motor component Tim17A downstream of the stress-regulated translational attenuation induced by the eukaryotic initiation factor 2α (eIF2α) phosphorylation (*Rainbolt, Saunders & Wiseman, 2015; Rainbolt et al., 2013*). The decrease in Tim17A protein level attenuates the general...
mitochondrial protein import and promotes the induction of the mito-UPR-associated proteostasis genes and stress-responsive genes.

Another intriguing function of Yme1l1 is related to cellular phospholipid metabolism. Yme1l1 drives the degradation of the PRELI-like protein family in the intermembrane space, including Ups1 and Ups2 in the absence of their binding partner Mdm35, a member of the twin Cx/C protein family (*Potting et al., 2010*). The Ups1 and Ups2 proteins were shown to regulate the accumulation of cardiolipin and phosphatidylethanolamine in the mitochondria (*Tamura et al., 2009*). Recent studies have also highlighted the role of Yme1l1 in metabolic reprogramming by rewiring the mitochondrial proteome under hypoxic and nutrient-deprived conditions (*MacVicar et al., 2019*). This metabolic adaptation is operated through the mTORC1-LIPIN-YME1L1 axis. The inhibition of mTORC1 activates LIPIN, a phosphatidic acid phosphatase that causes a decrease in the phosphatidylethanolamine levels in the mitochondrial membrane and subsequently activates Yme1l1. Under these conditions, the enhanced degradation of the protein translocases by activated Yme1l1 inhibits mitochondrial biogenesis. It promotes the metabolic flux of Tricarboxylic acid (TCA) intermediates towards anaplerotic biosynthetic reactions in preexisting mitochondria. These events are critical for the growth of solid tumors, such as pancreatic ductal adenocarcinomas (PDACs), for the anchorage-independent growth of the cells, and for the proliferation of cells in the presence of glutamine as a carbon source. The Yme1l1 is not only required for the development of specific cancer subtypes but also plays a role in the maintenance and self-renewal of neural stem and progenitor cells (NSPCs), and conditional deletion of the protease promotes stem cell exhaustion and pool depletion (*Wani et al., 2022*). The *YME1L1* deletion rewired cellular metabolism in these cells, including a significant reduction in the mitochondrial fatty acid oxidation, and activated a differentiation program in NSPCs.

**Lon protease**

Lon is the master AAA+ protease that protects against protein aggregation in the mitochondria by degrading the misfolded proteins. The homozygous or compound-heterozygous mutations in the Lon protease are associated with a multisystem developmental disorder known as CODAS syndrome, characterized by cerebral, ocular, dental, auricular, and skeletal anomalies (*Fig. 1A*) (*Strauss et al. 2015*). These mutations are clustered in the AAA+ domain, causing a defect in the protease activity. The lymphoblastoid cell lines harboring these mutant substitutions had swollen mitochondria with electron-dense inclusions, abnormal cristae structure, and a defect in the RC activity. The mutation in the proteolytic domain has also been shown to cause the atypical CODAS syndrome with cerebellar atrophy of high intensity, regression, and involuntary movement. However, the molecular basis of the defect for this mutation is not entirely understood (*Inui et al., 2017*). Additionally, mutations in the Lon protease are associated with a broad spectrum of diseases, including substitution at Pro761Leu in the proteolytic domain causes profound neurodegeneration with progressive cerebellar atrophy, hypotonia, muscle weakness, and intellectual disability (*Nimmo et al., 2019*). Interestingly, the cultured fibroblast from the affected individuals exhibited electron-dense inclusions in...
the mitochondria, regular activity of the RC complexes, and glucose-repressed oxygen consumption, while the galactose and palmitic acid utilization were unaffected. Notably, these fibroblasts also had reduced pyruvate dehydrogenase (PDH) activity and elevated intracellular lactate: pyruvate ratios caused by an increase in the phosphorylated E1α subunit of PDH. A recent report has identified a recessive mutation in the N-terminal substrate recognition domain of the Lon protease at aspartate 436 to asparagine, causing a form of mitochondrial cytopathy with early onset ataxia, developmental delay, emotional outbursts, speech and swallowing difficulties, and hypotonia (*Hannah-Shmouni et al., 2019*). The muscle biopsy from patients revealed increased oxidative stress, a block in autophagy, reduced mitochondrial state 3 respiration, and intra-mitochondrial globular inclusions. The homozygous knockout of Lon is lethal in mice and *Drosophila*, while the RNAi-mediated knockdown is associated with shortened lifespan and behavioral deficits (*Pareek et al., 2018; Quirós et al., 2014*). Deleting the Lon protease homolog in worms (lonp-1) is viable but accompanied by disturbed mitochondrial homeostasis, ROS accumulation, impaired growth, behavior, and lifespan (*Taouktsi et al., 2022*).

In addition to the m-AAA proteases, Lon protease has also been shown to regulate the various aspects of the mitochondrial gene expression machinery (Fig. 2). The Lon protease regulates mitochondrial DNA copy number by controlling the mitochondrial transcription factor A (TFAM) levels in *Drosophila S2* cells (*Matsushima, Goto & Kaguni, 2010*). The heterodimer of mitochondrial seryl-tRNA synthetase (SerRS2) and its paralog SLIMP protein bridges the interaction between TFAM and Lon protease, thereby promoting the TFAM degradation in S2 cells (*Picchioni et al., 2019*). While in mammalian cells, Lon protease promotes the degradation of TFAM phosphorylated by a cAMP-dependent protein kinase, which impairs its binding to DNA (*Lu et al., 2013*). Additionally, the Lon protease inhibition in fibroblast is associated with a defect in the maturation and solubility of a subset of proteins required for mitochondrial DNA maintenance and translation, including SSBP1, MTERFD3, and FASTKD2 (*Zurita Rendón & Shoubridge, 2018*). Depleting Lon in these cell lines also resulted in the loss of mitochondrial DNA, suppression of mitochondrial translation associated with impaired ribosome biogenesis, protein aggregates in the matrix, and activation of the ISR pathway. Notably, inhibition of the Lon protease in Hela cell lines caused defects in the turnover of mitochondrial pre-RNA processing nuclease MRPP3, followed by accumulation of many unprocessed mitochondrial transcripts and arrest in the mitochondrial translation (*Münch & Harper, 2016*).

The Lon protease has also been implicated in tumorigenesis, and heterozygous Lon mice are protected against colorectal cancer and skin papillomas induced by the treatment of 7,12-dimethylbenzanthracene and tetradecanoylphorbol acetate (DMBA/TPA) (*Quirós et al., 2014*). Higher expression of Lon protease is a poor prognosis marker and correlates with poor survival in human colorectal cancer and melanoma. The Lon protease-induced metabolic reprogramming, including reduction in mitochondrial oxidative phosphorylation (OXPHOS) capacity and increase in glycolysis, supports the proliferation of tumor cells and metastasis. In addition to its protease function, Lon protease also possesses chaperone properties, and this function of Lon is critical for its
anti-apoptosis activity. The increased Lon expression sequestered the P53 in the mitochondrial matrix and prevented both the transcription-dependent (by reducing the expression of P53 target genes in the nucleus) and independent (by preventing the loss of mitochondrial membrane potential and the release of apoptotic proteins cytochrome C and SMAC/Diablo in the cytosol) functions of P53 and thereby inhibited the apoptosis and promoted tumorigenesis (Sung et al., 2018). The high expression levels of Lon protease correlate positively in oral squamous cell carcinoma (OSCC) patients.

One of the well-established functions of the Lon protease is to degrade oxidatively damaged proteins in the mitochondria (Fig. 2). The aconitase’s oxidized form was among the first reported substrates of the Lon protease (Bota & Davies, 2002). Subsequently, the oxidized form of several other proteins, including mitochondrial stress proteins such as Hsp78, Hsp60, Sod2, prohibitins, mitochondrial metabolic enzymes such as pyruvate dehydrogenase complex, alpha keto glutarate dehydrogenase complex, ketol acid reductoisomerase, mitochondrial ribosomal proteins Mrp20 and respiratory chain subunits such as Qcr2 (complex III), Rip1 (complex III), Cox4 (complex IV), and ATP1,2 and 7 (complex V) exhibited altered abundance in Pim1 (Lon protease homolog in yeast) deficient yeast cells (Bayot et al., 2010). In conjunction with the Clp protease, the Lon protease degrades subunits of the matrix exposed ROS generating arm of the complex I, including NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFB8, and NDUFA9 in depolarized mitochondria of SH-SY5Y and HeLa cells after CCCP treatment (Pryde, Taanman & Schapira, 2016). The Lon protease also protects against oxidative stress in Drosophila (Pomatto et al., 2017). Notably, the sex-specific isoforms of Lon protease confer protection against hydrogen peroxide-induced stress in female flies and paraquat-induced stress in male flies. The increase in oxidative stress is also associated with protein aggregation. The Lon protease degrades several misfolded proteins and protects against protein aggregation in the human mitochondria (Bezawork-Geleta et al., 2015). Recently, two independent reports have suggested that the chaperone activity of Lon protease is critical to prevent aggregation of several mitochondrial proteins, including DnaJ co-chaperone (TID1/DNAJA3), succinate dehydrogenase complex flavoprotein subunit A (SDHA), ClpX and mitochondrial heat shock protein 75 kDa (TRAP1/mTHSP75) (Matsushima et al., 2021; Pollecker, Sylvester & Voos, 2021). Not only this, but Lon also forms a complex with the components of the ‘TOM’ and ‘TIM’ machinery and maintains the soluble state of newly imported proteins, and degrades the unprocessed form of mitochondrial proteins with signal sequence (Matsushima et al., 2021).

Almost any biological process related to mitochondria involves the regulation by the Lon protease. The Lon protease regulates the pyruvate dehydrogenase kinase 4 (PDK4) content in cardiomyocytes mitochondria and thereby controls the activity of pyruvate dehydrogenase complex and metabolic flexibility (Crewe et al., 2017). The ISU (Iron-sulfur cluster assembly protein) protein involved in Fe/S cluster biogenesis is also a substrate of the Lon protease when the sulfur donor Nfs1 and J-protein cochaperone Jac1 (J-type Accessory Chaperone) do not bind it (Nitrogen-Fixing Bacteria S-Like Protein) (Ciesielski et al., 2016; Song, Marszalek & Craig, 2012). The Lon protease also degrades the Steroidogenic acute regulatory protein (StAR) protein which facilitates the rate-limiting
step in steroid biosynthesis, which is the transfer of cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane (Granot et al., 2007). The extensive repertoire of substrates for Lon protease makes it unarguably the master of all trades in the mitochondria.

**Clp protease**

The Caseinolytic mitochondrial matrix peptidase is a highly conserved member of the serine protease family residing in the mitochondrial matrix. In contrast to other proteases, which contain domains with protease and ATPase activity on the same polypeptide, the mitochondrial ClpP lacks ATP hydrolysis activity and only possesses the domain for the proteolytic activity that can digest small peptides without ATP requirement. Additionally, the ClpP, in conjunction with the chaperone and ATPase ClpX, can digest larger substrates in the matrix compartment. The ClpXP complex comprises the CLPP units arranged as a stacked heptameric ring with a proteolytic cavity flanked at both ends by ClpX (Fei et al., 2020). The recessive mutations in ClpP are associated with Perrault syndrome, a disease characterized by sensorineural hearing loss and ovarian dysgenesis (Jenkinson et al., 2013). The ClpP-deficient mouse model exhibited female and male infertility caused by disrupted spermatogenesis and ovarian follicular differentiation failures (Gispert et al., 2013). These mice also showed reduced lifespan, growth retardation, mild impairment in behavioral and respiratory chain activities, and activation of the Type I IFN responses through the Mitochondrial DNA–cGAS–STING signaling axis (Torres-Odio et al., 2021). Contrary to the mouse model, the deficiency of ClpP in fungal species Podospora anserine led to a healthy and increased lifespan, a phenotype that the expression of human ClpP can revert, demonstrating functional conservation between human and fungal ClpP (Fischer et al., 2013).

Over the past years, some of the substrates of ClpP protease have been reported highlighting its role in mitochondrial biology. The ClpP protease has been shown to determine the rate of mitochondrial protein synthesis and mitoribosome assembly by regulating the levels of various components of the transcription and translation machinery (Fig. 2). In the human cell culture system, the deficiency of ClpP causes the accumulation of ERAL1 (Era Like 12S Mitochondrial RNA Chaperone 1), a putative 12S rRNA chaperone, whose timely removal from the small mitochondrial ribosomal subunit is essential for the complete maturation and assembly of the mitochondrial ribosome and the normal rate of mitochondrial translation (Szczepanowska et al., 2016). In Drosophila Schneider S2 cells, the knockdown of ClpP protease caused the accumulation of leucine-rich pentatricopeptide repeat domain-containing protein 1 (LRPPRC1) followed by an increase of mitochondrial mRNAs, accumulation of some unprocessed mitochondrial transcripts, and repression of the mitochondrial translation (Matsushima et al., 2017).

Mitochondria are fundamental for cellular metabolism and regulate several metabolic pathways related to glucose homeostasis and fatty acid oxidation. Regarding this, the deficiency of the ClpP protease in mice is metabolically beneficial and has been associated with the lean body phenotype, increased energy expenditure, improved glucose
homeostasis, insulin resistance, protection from high fat diet-induced obesity, and protection from hepatic steatosis (Becker et al., 2018; Bhaskaran et al., 2018). However, the depletion of ClpP also caused a decline in brown adipocyte function, impaired cold-induced thermogenesis, and increased fatty acid oxidation in white adipose tissues. It remains to be seen if targeting the ClpP protease using specific inhibitors in fat tissues will help combating obesity-related disorders in humans.

In Caenorhabditis elegans, the ClpP homolog (CLPP-1) is required for the mito-UPR signaling (Fig. 2) (Haynes et al., 2007). The CLPP-1-mediated proteolysis of misfolded proteins is an early step necessary for UPR signaling in worms. However, the function of the ClpP in the UPR signaling is debated, and it has been shown in cell culture and mouse models that the ClpP is dispensable for the mito-UPR (Seiferling et al., 2016; Rumyantseva, Popovic & Trifunovic, 2022). Surprisingly, the deficiency of the ClpP protease ameliorated the symptoms of mitochondrial cardiomyopathy and mitochondrial encephalopathy caused by the tissue-specific deficiency of the mitochondrial aspartyl tRNA synthase, DARS2 (Seiferling et al., 2016; Rumyantseva, Popovic & Trifunovic, 2022; Dogan et al., 2014). These findings have demonstrated that the mammalian ClpP is neither required for nor regulates the UPR and introduces ClpP as a possible novel target for therapeutic intervention in mitochondrial diseases characterized by respiratory chain and mitochondrial gene expression dysfunctions.

The ClpP is overexpressed in approximately 40% of Acute Myeloid Leukemia (AML) patients (Cole et al., 2015). The inhibition of the ClpP protease by knockdown or by using chemical inhibitors, including A2-32-01, reduced the growth and viability of several AML cell lines with high ClpP expression. Still, it did not affect other cell lines with low levels of ClpP. The effects of the ClpP-mediated growth inhibition on AML cell lines are partly mediated by the increased amount of misfolded complex II subunits, including succinate dehydrogenase A (SDHA), impaired complex II activity, reduced oxygen consumption rates (OCR), and increased ROS (Cole et al., 2015). An independent report has further substantiated the role of ClpP in cancer. It has shown that ClpP is universally overexpressed in primary and metastatic human cancer, correlating with poor patient survival (Seo et al., 2016; Rivadeneira et al., 2015). Using proteomics analysis, this report showed that the ClpP forms a complex with the oncoprotein survivin and the Hsp90-like chaperone TRAP-1. Together, they regulated the solubility and function of the oxidative phosphorylation Complex II subunit succinate dehydrogenase B (SDHB). Furthermore, the inhibition of the ClpP impaired oxidative capacity by causing the accumulation of misfolded SDHB, promoted oxidative stress, and ceased critical downstream signals essential for tumor cell proliferation, invasion, and metastatic dissemination in vivo (Seo et al., 2016). Not only inhibition but the hyperactivation of ClpP by imipridones, including ONC201 and ONC212, has been shown to selectively kill the malignant cells by causing a reduction in the respiratory chain complex subunits, impairing oxidative phosphorylation and mitochondrial morphology. At the same time, these compounds do not exert any effects on non-cancer cells (Graves et al., 2019; Ishizawa et al., 2019).

The unfoldase ClpX has functions beyond its partner ClpP in eukaryotes, including its role in heme biosynthesis, which is conserved from yeast to mammalian vertebrates
The ClpX catalyzes the incorporation of a cofactor pyridoxal phosphate (PLP) into the ALA (5-aminolevulinic acid) synthase apoenzyme by partially unfolding it and thereby generating an active form of ALA synthase and stimulates ALA synthesis, which is the first step of heme biosynthesis (Kardon et al., 2015; Kardon et al., 2020). The morpholino-mediated knockdown of ClpX in D. rerio. Zebrafish caused defects in red blood cell development, indicating that the ClpX is Important for vertebrate heme biosynthesis and erythropoiesis. Additionally, the dominant mutation in ClpX has been reported that results in the pathological accumulation of the heme biosynthesis intermediate protoporphyrin IX (PPIX) in erythroid cells, causing erythropoietic protoporphyria (EPP) in the affected patients (Yien et al., 2017).

FUTURE PERSPECTIVE

What substrates and pathways are regulated by the mitochondrial AAA+ protease family?

The mitochondrial AAA+ family of proteases is believed to provide the first line of defense against any insults. The importance of this protease family is best exemplified by the severe neurodegenerative diseases caused by mutations in their respective genes, including Hereditary Spastic Paraplegia (HSP), SpinoCerebellar Ataxia, CODAS, and Perrault syndrome. While these proteases have been studied for decades, remarkably little is known about their precise biological roles, their substrates in the mitochondria, and the mechanisms by which their mutational inactivation causes disease in humans. It is not entirely known whether manipulating the levels of selective candidate AAA+ substrates influences the behavioral and neurodegenerative phenotypes of AAA+-deficient organisms.

Do the mitochondrial AAA+ proteases degrade unfolded cytoplasmic proteins, including those involved in neurodegenerative diseases?

A common characteristic of neurodegenerative diseases is the co-occurrence of dysfunctional mitochondria and cytoplasmic protein aggregates (Ross & Poirier, 2004; Ruan et al., 2020; Vicario et al., 2018; Gao et al., 2019). Recent work in yeast and cell lines suggests that such aggregates can be imported into the mitochondria and degraded by the AAA+ proteases (Ruan et al., 2017; Li et al., 2019; Hu et al., 2019). The various protease-deficient disease models offer an excellent way to test in a system whether the aggregates associated with common neurodegenerative diseases are degraded in the mitochondria. It is tempting to speculate if the overexpression and downregulation of AAA+ proteases in various models of Parkinson’s disease and Alzheimer’s disease (strains known to develop cytoplasmic protein aggregates) will modify the behavioral phenotypes and extend the life expectancy of the organism. The recent work showing that the TDP43 levels are regulated by Lon protease in the Drosophila model offers a glimpse of hope that AAA+ protease might have a role in the degradation of the cytoplasmic pathological aggregates (Wang et al., 2019).
Is mitochondrial translational inhibition and activation of the mito-UPR a general response to any type of mitochondrial proteotoxic stress, and how does it arise?

One of the most exciting findings from recently published work on AAA+ proteases is that the respiratory chain defects resulting from the inactivation of the proteases are caused by a global reduction of the mitochondrial translation field (Zurita Rendón & Shoubridge, 2018; Münch & Harper, 2016). While extensive work on the ER and cytoplasmic protein unfolding stress response pathways have documented how unfolded protein stress triggers cytoplasmic translational arrest, the mechanism by which the mito-UPR triggers mitochondrial translational inhibition is not entirely understood. The recently published findings lay the foundation for studies aimed to test: (1) the precise mechanism by which the mito-UPR may inhibit mitochondrial translation. In the nematode Caenorhabditis elegans, the mito-UPR pathway requires the transcription factor ATFS-1; the mammalian ATFS-1 equivalent has only recently been identified (Fiorese et al., 2016). It is unclear if the targets of the ATFS-1 homolog in the mammalian system play any role in mitochondrial translational attenuation and chaperone upregulation under proteotoxic stress; (2) whether manipulations that oppose protein misfolding can restore translation under stress conditions; and (3) whether the mitochondrial translational inhibition during proteotoxic stress is beneficial or harmful.

ABBREVIATIONS

AAA+ ATPase Associated with diverse cellular Activities
QC Quality Control
ATP Adenosine Tri Phosphate
RC Respiratory Chain
ROS Reactive Oxygen Species
TOM Translocase of the Outer Membrane
TIM Translocase of the Inner Membrane
NDP52 Nuclear dot protein 52
TAX1BP1 Human T-Cell Leukemia Virus Type I Binding Protein 1
NBR1 Neighbor of BRCA1 gene 1
CMT2A Charcot-Marie-Tooth Type 2A
DOA Dominant Optic Atrophy
FtsH Filamentous temperature sensitive H
EM Electron Microscopy
Afg3l2 ATPase family gene 3-like 2
OTC Ornithine transcarbamylase
MDH Malate Dehydrogenase
SCA Spinocerebellar Ataxia
HSP Hereditary Spastic Paraplegia
MCU Mitochondrial Calcium Uniporter
EMRE Essential MCU Regulator
mPTP  mitochondrial permeability transition pore
AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
MPP   Matrix Processing Peptidase
ETC   Electron Transport Chain
ISR   Integrated Stress Signaling
UPR   Unfolded Protein Response
CL    Cardiolipin
PE    Phosphatidylethanolamine
PDAC  Pancreatic Ductal Adenocarcinomas
NSPC  Neural Stem and Progenitor Cells
CODAS Cerebral, Ocular, Dental, Auricular, and Skeletal
SLP2  Stomatin-like protein 2
ISR   integrated stress response
OSCC  Oral Squamous Cell Carcinoma
LRPPRC1 leucine-rich pentatricopeptide repeat domain-containing protein 1
OCR   Oxygen Consumption Rates
SDH   Succinate Dehydrogenase
EPP   Erythropoietic protoporphyria
OXPHOS Oxidative Phosphorylation
PDK4  Pyruvate dehydrogenase kinase 4
ISU   Iron SUlfur cluster assembly protein
StAR  Steroidogenic Acute Regulatory protein
Nfs1  Nitrogen-Fixing Bacteria S-Like Protein
Jac1  J-type Accessory Chaperone
ERAL1 Era Like 12S Mitochondrial RNA Chaperone 1
AML   Acute Myeloid Leukemia
ALA   5-aminolevulinic acid
PPIX  protoporphyrin IX

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
The author received no funding for this work.

Competing Interests
The author declares that they have no competing interests.

Author Contributions
• Gautam Pareek conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
Data Availability
The following information was supplied regarding data availability:
This is a literature review.

REFERENCES

Almajan ER, Richter R, Paeger L, Martinelli P, Barth E, Decker T, Larsson NG, Kloppenburg P, Langer T, Rugarli EI. 2012. AFG3L2 supports mitochondrial protein synthesis and purkinje cell survival. *Journal of Clinical Investigation* **122**(11):4048–4058 DOI 10.1172/JCI64604.

Arlt H, Tauer R, Feldmann H, Neupert W, Langer T. 1996. The YTA10–12 complex, an Aaa protease with chaperone-like activity in the inner membrane of mitochondria. *Cell* **85**(6):875–885 DOI 10.1016/S0092-8674(00)81271-4.

Atorino L, Silvestri L, Koppen M, Cassina L, Ballabio A, Marconi R, Langer T, Casari G. 2003. Loss of M-Aaa protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia. *Journal of Cell Biology* **163**(4):777–787 DOI 10.1083/jcb.200304112.

Baker BM, Nargund AM, Sun T, Haynes CM. 2012. Protective coupling of mitochondrial function and protein synthesis via the eiF2α kinase GCN-2. *PLOS Genetics* **8**(6):e1002760 DOI 10.1371/journal.pgen.1002760.

Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, Sancak Y, Bao XR, Strittmatter L, Goldberger O, Bogorad RL, Koteliansky V, Mootha VK. 2011. Integrative genomics identifies mcu as an essential component of the mitochondrial calcium uniporter. *Nature* **476**(7360):341–345 DOI 10.1038/nature10234.

Bayot A, Gareil M, Rogowska-Wrzesinska A, Roepstorff P, Friguet B, Bulteau AL. 2010. Identification of novel oxidized protein substrates and physiological partners of the mitochondrial atp-dependent lon-like protease Pim1. *Journal of Biological Chemistry* **285**(15):11445–11457 DOI 10.1074/jbc.M109.065425.

Becker C, Kukat A, Szczepanowska K, Hermans S, Senft K, Brandscheid CP, Maiti P, Trifunovic A. 2018. Clpp deficiency protects against metabolic syndrome but hinders adaptive thermogenesis. *EMBO Reports* **19**(5):e45126 DOI 10.15252/embr.201745126.

Bernardi P. 2013. The mitochondrial permeability transition pore: a mystery solved? *Frontiers in Physiology* **4**:95 DOI 10.3389/fphys.2013.00095.

Bezawork-Geleta A, Brodie EJ, Dougan DA, Truscott KN. 2015. Lon is the master protease that protects against protein aggregation in human mitochondria through direct degradation of misfolded proteins. *Scientific Reports* **5**(1):17397 DOI 10.1038/srep17397.

Bhaskaran S, Pharaoh G, Ranjit R, Murphy A, Matsuzaki S, Nair BC, Forbes B, Gispert S, Auburger G, Humphries KM, Kinter M, Griffin TM, Deepa SS. 2018. Loss of mitochondrial protease clpp protects mice from diet-induced obesity and insulin resistance. *EMBO Reports* **19**(3):275 DOI 10.15252/embr.201745009.

Bock FJ, Tait SWG. 2020. Mitochondria as multifaceted regulators of cell death. *Nature Reviews Molecular Cell Biology* **21**(2):85–100 DOI 10.1038/s41580-019-0173-8.

Bota DA, Davies KJ. 2002. Lon protease preferentially degrades oxidized mitochondrial aconitase by an atp-stimulated mechanism. *Nature Cell Biology* **4**(9):674–680 DOI 10.1038/ncb836.

Chan DC. 2020. Mitochondrial dynamics and its involvement in disease. *Annual Review of Pathology: Mechanisms of Disease* **15**(1):235–259 DOI 10.1146/annurev-pathmechdis-012419-032711.
Chandel NS. 2015. Evolution of mitochondria as signaling organelles. *Cell Metabolism* 22(2):204–206. DOI 10.1016/j.cmet.2015.05.013.

Chen H, Chan DC. 2017. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. *Cell Metabolism* 26(1):39–48. DOI 10.1016/j.cmet.2017.05.016.

Ciesielski SJ, Schilke B, Marszalek J, Craig EA. 2016. Protection of scaffold protein iso from degradation by the lon protease Pim1 as a component of fe-s cluster biogenesis regulation. *Molecular Biology of the Cell* 27(7):1060–1068. DOI 10.1091/mbc.E15-12-0815.

Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yao SJ, Hay BA, Guo M. 2006. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. *Nature* 441(7097):1162–1166. DOI 10.1038/nature04779.

Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, Bashir S, Ramakrishnan A, Leung E, Qia YH, Zhang N, Combes KR, Ketela T, Lin F, Houry WA, Aman A, Al-Awar R, Zheng W, Wienholds E, Xu CJ, Dick J, Wang JC, Moffat J, Minden MD, Eaves CJ, Bader GD, Hao Z, Kornblau SM, Raught B, Schimmer AD. 2015. Inhibition of the mitochondrial protease clp as a therapeutic strategy for human acute myeloid leukemia. *Cancer Cell* 27(6):864–876. DOI 10.1016/j.ccell.2015.05.004.

Crewe C, Schafer C, Lee I, Kinter M, Szweda LI. 2017. Regulation of pyruvate dehydrogenase kinase 4 in the heart through degradation by the lon protease in response to mitochondrial substrate availability. *Journal of Biological Chemistry* 292(1):305–312. DOI 10.1074/jbc.M116.754127.

Deshwal S, Fiedler KU, Langer T. 2020. Mitochondrial proteases: multifaceted regulators of mitochondrial plasticity. *Annual Review of Biochemistry* 89(1):501–528. DOI 10.1146/annurev-biochem-062917-012739.

Di Bella D, Lazzaro F, Brusco A, Plumbi M, Battaglia G, Pastore A, Finardi A, Cagnoli C, Tempia F, Frontali M, Veneziano L, Sacco T, Boda E, Brussino A, Bonn F, Castellotti B, Baratta S, Mariotti C, Gellera C, Fracasso V, Magri S, Langer T, Plevani P, Donato SDi, Muzi-Falconi M, Taroni F. 2010. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. *Nature Genetics* 42(4):313–321. DOI 10.1038/ng.544.

Ding B, Martin DW, Rampello AJ, Glynn SE. 2018. Dissecting substrate specificities of the mitochondrial Afg3l2 protease. *Biochemistry* 57(28):4225–4235. DOI 10.1021/acs.biochem.8b00565.

Dogan SA, Pujol C, Maiti P, Kukat A, Wang S, Hermans S, Senft K, Wibom R, Rugarli EI, Trifunovic A. 2014. Tissue-specific loss of Dars2 activates stress responses independently of respiratory chain deficiency in the heart. *Cell Metabolism* 19(3):458–469. DOI 10.1016/j.cmet.2014.02.004.

Ehses S, Raschke I, Mancuso G, Bernacchia A, Geimer S, Tondera D, Martinou JC, Westermann B, Rugarli EI, Langer T. 2009. Regulation of opa1 processing and mitochondrial fusion by M-Aaa protease isoenzymes and oma1. *Journal of Cell Biology* 187(7):1023–1036. DOI 10.1083/jcb.200906084.

Fei X, Bell TA, Jenni S, Stinson BM, Baker TA, Harrison SC, Sauer RT. 2020. Structures of the atp-fueled clp-xp proteolytic machine bound to protein substrate. *Elife* 9:213. DOI 10.7554/elife.52774.

Ferreirinha F, Quattrini A, Pirozzi M, Valsecchi V, Dina G, Broccoli V, Auricchio A, Piemonte F, Tozzi G, Gaeta L, Casari G, Ballabio A, Rugarli EI. 2004. Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. *Journal of Clinical Investigation* 113(2):231–242. DOI 10.1172/JCI200420138.
Fiorese CJ, Schulz AM, Lin YF, Rosin N, Pellegrino MW, Haynes CM. 2016. The transcription factor Atf5 mediates a mammalian mitochondrial upr. Current Biology 26(15):2037–2043 DOI 10.1016/j.cub.2016.06.002.

Fischer F, Weil A, Hamann A, Osiewacz HD. 2013. Human clpp reverts the longevity phenotype of a fungal clpp deletion strain. Nature Communications 4(1):1397 DOI 10.1038/ncomms2397.

Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J, Voeltz GK. 2011. Er tubules mark sites of mitochondrial division. Science 334(6054):358–362 DOI 10.1126/science.1207385.

Gao J, Wang L, Yan T, Perry G, Wang X. 2019. Tdp-43 proteinopathy and mitochondrial abnormalities in neurodegeneration. Molecular and Cellular Neuroscience 100:103396 DOI 10.1016/j.mcn.2019.103396.

Ge P, Dawson VL, Dawson TM. 2020. Pink1 and parkin mitochondrial quality control: a source of regional vulnerability in parkinson’s disease. Molecular Neurodegeneration 15(1):20 DOI 10.1186/s13024-020-00367-7.

Gispert S, Parganlija D, Klinkenberg M, Drose S, Wittig I, Mittelbronn M, Grzmił P, Koob S, Hamann A, Walter M, Buchel F, Adler T, Hrabe de Angelis M, Busch DH, Zell A, Reichert AS, Brandt U, Osiewacz HD, Jendrach M, Auburger G. 2013. Loss of mitochondrial peptidase clpp leads to infertility, hearing loss plus growth retardation via accumulation of clpx, mtDNA and inflammatory factors. Human Molecular Genetics 22(24):4871–4887 DOI 10.1093/hmg/ddt338.

Glynn SE. 2017. Multifunctional mitochondrial aat proteases. Frontiers in Molecular Biosciences 4:34 DOI 10.3389/fmolb.2017.00034.

Granot Z, Kobiler O, Melamed-Book N, Eimerl S, Bahat A, Lu B, Braun S, Maurizi MR, Suzuki CK, Oppenheim AB, Orly J. 2007. Turnover of mitochondrial steroidalogenic acute regulatory (star) protein by lon protease: the unexpected effect of proteasome inhibitors. Molecular Endocrinology 21(9):2164–2177 DOI 10.1210/me.2005-0458.

Graves PR, Aponte-Collazo LJ, Fennell EMJ, Graves AC, Hale AE, Dicheva N, Herring LE, Gilbert TSK, East MP, McDonald IM, Lockett MR, Ashamalla H, Moorman NJ, Karanewska DS, Iwanowicz EJ, Holmuhamedov E, Graves LM. 2019. Mitochondrial protease clpp is a target for the anticancer compounds onc201 and related analogues. ACS Chemical Biology 14(5):1020–1029 DOI 10.1021/acschembio.9b00222.

Greene AW, Grenier K, Aguileta MA, Muise S, Farazifard R, Haque ME, McBride HM, Park DS, Fon EA. 2012. Mitochondrial processing peptidase regulates Pink1 processing, import and parkin recruitment. EMBO Reports 13(4):378–385 DOI 10.1038/embr.2012.14.

Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. 2003. Mitochondrial pathology and apoptotic muscle degeneration in drosophila parkin mutants. Proceedings of the National Academy of Sciences of the United States of America 100(7):4078–4083 DOI 10.1073/pnas.0737556100.

Gur E, Sauer RT. 2008. Recognition of misfolded proteins by lon, a Aaa(+) protease. Genes & Development 22(16):2267–2277 DOI 10.1101/gad.1670908.

Gustafsson CM, Falkenberg M, Larsson NG. 2016. Maintenance and expression of mammalian mitochondrial DNA. Annual Review of Biochemistry 85(1):133–160 DOI 10.1146/annurev-biochem-060815-014402.

Hannah-Shmouni F, MacNeil L, Brady L, Nilsson MI, Tarnopolsky M. 2019. Expanding the clinical spectrum of Lonp1-related mitochondrial cytopathy. Frontiers in Neurology 10:2019–2981 DOI 10.3389/fneur.2019.00981.

Hartmann B, Wai T, Hu H, MacVicar T, Musante L, Fischer-Zirnsak B, Stenzel W, Gräf R, van den Heuvel L, Ropers HH, Wienker TF, Hübner C, Langer T, Kaindl AM. 2016.
Homozygous YME1L1 mutation causes mitochondriopathy with optic atrophy and mitochondrial network fragmentation. *Elife* 5:919 DOI 10.7554/eLife.16078.

Haynes CM, Petrova K, Benedetti C, Yang Y, Ron D. 2007. Clpp mediates activation of a mitochondrial unfolded protein response in C. elegans. *Developmental Cell* 13(4):467–480 DOI 10.1016/j.devcel.2007.07.016.

Hu D, Sun X, Liao X, Zhang X, Zarabi S, Schimme A, Hong Y, Ford C, Luo Y, Qi X. 2019. Alpha-synuclein suppresses mitochondrial protease clpp to trigger mitochondrial oxidative damage and neurotoxicity. *Acta Neuropathologica* 137(6):939–960 DOI 10.1007/s00401-019-01993-2.

Hällberg BM, Larsson NG. 2014. Making proteins in the powerhouse. *Cell Metabolism* 20(2):226–240 DOI 10.1016/j.cmet.2014.07.001.

Inui T, Anzai M, Takezawa Y, Endo W, Kokisaka Y, Kikuchi A, Onuma A, Kure S, Nishino I, Ohba C, Saito H, Matsumoto N, Haginoya K. 2017. A novel mutation in the proteolytic domain of Lonp1 causes atypical codas syndrome. *Journal of Human Genetics* 62(6):653–655 DOI 10.1038/jhg.2017.11.

Ishihara N, Fujita Y, Oka T, Mihara K. 2006. Regulation of mitochondrial morphology through proteolytic cleavage of opa1. *The EMBO Journal* 25(13):2966–2977 DOI 10.1038/sj.emboj.7601184.

Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mahanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. 2019. Mitochondrial clpp-mediated proteolysis induces selective cancer cell lethality. *Cancer Cell* 35(5):721–37.e9 DOI 10.1016/j.ccell.2019.03.014.

Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos MJ, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, de Yebenes JG. 2003. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. *Human Molecular Genetics* 12(18):2277–2291 DOI 10.1093/hmg/ddg239.

Jenkinson EM, Rehman AU, Walsh T, Clayton-Smith J, Lee K, Morell RJ, Drummond MC, Khan SN, Naeem MA, Rauf B, Billington N, Schultz JM, Urquhart JE, Lee MK, Berry A, Hanley NA, Mehta S, Cilliers D, Clayton PE, Kingston H, Smith MJ, Warner TT, Black GC, Trump D, Davis JR, Ahmad W, Leal SM, Riazuddin S, King MC, Friedman TB, Newman WG. 2013. Perrault syndrome is caused by recessive mutations in clpp, encoding a mitochondrial atp-dependent chambered protease. *American Journal of Human Genetics* 92(4):605–613 DOI 10.1016/j.ajhg.2013.02.013.

Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ. 2010. Mitochondrial membrane potential regulates pink1 import and proteolytic destabilization by parl. *Journal of Cell Biology* 191(5):933–942 DOI 10.1083/jcb.201008084.

Kanki T, Wang K, Cao Y, Baba M, Klionsky DJ. 2009. Atg32 is a mitochondrial protein that confers selectivity during mitophagy. *Developmental Cell* 17(1):98–109 DOI 10.1016/j.devcel.2009.06.014.

Kardon JR, Moroco JA, Engen JR, Baker TA. 2020. Mitochondrial clpx activates an essential biosynthetic enzyme through partial unfolding. *Elife* 9:274 DOI 10.7554/eLife.54387.
Kardon JR, Yien YY, Huston NC, Branco DS, Hildick-Smith GJ, Rhee KY, Paw BH, Baker TA. 2015. Mitochondrial clpx activates a key enzyme for heme biosynthesis and erythropoiesis. *Cell* 161(4):858–867 DOI 10.1016/j.cell.2015.04.017.

Kauppila TES, Kauppila JHK, Larsson NG. 2017. Mammalian mitochondria and aging: an update. *Cell Metabolism* 25(1):57–71 DOI 10.1016/j.cmet.2016.09.017.

Kondadi AK, Wang S, Montagner S, Kladt N, Korwitz A, Martinelli P, Herholz D, Baker MJ, Schauss AC, Langer T, Rugarli EI. 2014. Loss of the M-Aaa protease subunit AFG3L2 causes mitochondrial transport defects and tau hyperphosphorylation. *EMBO Journal* 33(9):1011–1026 DOI 10.1002/embj.201387009.

König T, Tröder SE, Bakka K, Korwitz A, Richter-Dennerlein R, Lampe PA, Patron M, Mühlmeister M, Guerrero-Castillo S, Brandt T, Lauria I, Paggio A, Rizzuto R, Rugarli EI, Stefani DDe, Langer T. 2016. The M-Aaa protease associated with neurodegeneration limits mcu activity in mitochondria. *Molecular Cell* 64(1):148–162 DOI 10.1016/j.molcel.2016.08.020.

Kazarou M, Sliter DA, Kane LA, Sarraf SA, Wang C, Burman JL, Sideris DP, Fogel AI, Youle RJ. 2015. The ubiquitin kinase pink1 recruits autophagy receptors to induce mitophagy. *Nature* 524(7565):309–314 DOI 10.1038/nature14893.

Lee JJ, Sanchez-Martinez A, Zarate AM, Benincá C, Mayor U, Clague MJ, Whitworth AJ. 2018. Basal mitophagy is widespread in drosophila but minimally affected by loss of pink1 or parkin. *Journal of Cell Biology* 217(5):1613–1622 DOI 10.1083/jcb.20181044.

Lee Y, Stevens DA, Kang SU, Jiang H, Lee YI, Ko HS, Scarffe LA, Umanah GE, Kang H, Ham S, Kam TI, Allen K, Brahmacari S, Kim JW, Neifert S, Yun SP, Fiesel FC, Springer W, Dawson VL, Shin JH, Dawson TM. 2017. Pink1 primes parkin-mediated ubiquitination of paris in dopaminergic neuronal survival. *Cell Reports* 18(4):918–932 DOI 10.1016/j.celrep.2016.12.090.

Leonhard K, Guiard B, Pellecchia G, Tzagoloff A, Neupert W, Langer T. 2000. Membrane protein degradation by aap proteases in mitochondria: extraction of substrates from either membrane surface. *Molecular Cell* 5(4):629–638 DOI 10.1016/S1097-2765(00)80242-7.

Leonhard K, Stiegler A, Neupert W, Langer T. 1999. Chaperone-like activity of the Aaa domain of the yeast Yme1 Aaa protease. *Nature* 398(6725):348–351 DOI 10.1038/18704.

Li Y, Xue Y, Xu X, Wang G, Liu Y, Wu H, Li W, Wang Y, Chen Z, Zhang W, Zhu Y, Ji W, Xu T, Liu L, Chen Q. 2019. A mitochondrial Fundc1/Hsc70 interaction organizes the proteostatic stress response at the risk of cell morbidity. *EMBO Journal* 38(3):30470 DOI 10.15252/embj.201798786.

Lu B, Lee J, Nie X, Li M, Morozov YI, Venkatesh S, Bogenhagen DF, Temiakov D, Suzuki CK. 2013. Phosphorylation of human tfam in mitochondria impairs DNA binding and promotes degradation by the Aaa+ lon protease. *Molecular Cell* 49(1):121–132 DOI 10.1016/j.molcel.2012.10.023.

MacVicar T, Ohba Y, Nolte H, Mayer FC, Tatsuta T, Sprenger HG, Lindner B, Zhao Y, Li J, Bruns C, Krüger M, Habich R, Mierer J, Schwarzer R, Pasparakis M, Henschke S, Brüning JC, Zamboni N, Langer T. 2019. Lipid signalling drives proteolytic rewiring of mitochondria by Yme1l. *Nature* 575(7782):361–365 DOI 10.1038/s41586-019-1738-6.

Maltecca F, Aghaie A, Schroeder DG, Cassina L, Taylor BA, Phillips SJ, Malaguti M, Previtali S, Guénet JL, Quattrini A, Cox GA, Casari G. 2008. The mitochondrial protease AFG3L2 is essential for axonal development. *Journal of Neuroscience* 28(11):2827–2836 DOI 10.1523/JNEUROSCI.4677-07.2008.

Pareek (2022), PeerJ, DOI 10.7717/peerj.14350
Maltecca F, Baseggio E, Consolato F, Mazza D, Podini P, Young SM Jr, Drago I, Bahr BA, Puliti A, Codazzi F, Quattrini A, Casari G. 2015. Purkinje neuron Ca2+ influx reduction rescues ataxia in SCA28 model. *Journal of Clinical Investigation* **125**(1):263–274. DOI 10.1172/JCI74770.

Maltecca F, Magnoni R, Cerri F, Cox GA, Quattrini A, Casari G. 2009. Haploinsufficiency of AFG3L2, the gene responsible for spinocerebellar ataxia type 28, causes mitochondria-mediated purkinje cell dark degeneration. *Journal of Neuroscience* **29**(29):9244–9254. DOI 10.1523/JNEUROSCI.1532-09.2009.

Martin I, Dawson VL, Dawson TM. 2011. Recent advances in the genetics of parkinson’s disease. *Annual Review of Genomics and Human Genetics* **12**(1):301–325. DOI 10.1146/annurev-genom-082410-101440.

Matsushima Y, Goto Y, Kaguni LS. 2010. Mitochondrial lon protease regulates mitochondrial DNA copy number and transcription by selective degradation of mitochondrial transcription factor a (Tfam). *Proceedings of the National Academy of Sciences of the United States of America* **107**(43):18410–18415. DOI 10.1073/pnas.1008924107.

Matsushima Y, Hirofuji Y, Aihara M, Yue S, Uchiumi T, Kaguni LS, Kang D. 2017. Drosophila protease clpx specifically degrades dmlrprc1 controlling mitochondrial mrna and translation. *Scientific Reports* **7**(1):8315. DOI 10.1038/s41598-017-08088-6.

Matsushima Y, Takahashi K, Yue S, Fujiyoshi Y, Yoshioka H, Aihara M, Setoyama D, Uchiumi T, Fukuchi S, Kang D. 2021. Mitochondrial lon protease is a gatekeeper for proteins newly imported into the matrix. *Communications Biology* **4**(1):974. DOI 10.1038/s42003-021-02498-z.

McBride HM, Neuspiel M, Wasiak S. 2006. Mitochondria: more than just a powerhouse. *Current Biology* **16**(14):R551–R560. DOI 10.1016/j.cub.2006.06.054.

McWilliams TG, Prescott AR, Allen GF, Tamjar J, Munson MJ, Thomson C, Muqit MM, Ganley IG. 2016. Mito-Qc illuminates mitophagy and mitochondrial architecture in vivo. *Journal of Cell Biology* **214**(3):333–345. DOI 10.1083/jcb.201603039.

Milenkovic D, Blaza JN, Larsson NG, Hirst J. 2017. The enigma of the respiratory chain supercomplex. *Cell Metabolism* **25**(4):765–776. DOI 10.1016/j.cmet.2017.03.009.

Mishra P, Carelli V, Manfredi G, Chan DC. 2014. Proteolytic cleavage of opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation. *Cell Metabolism* **19**(4):630–641. DOI 10.1016/j.cmet.2014.03.011.

Murphy MP. 2009. How mitochondria produce reactive oxygen species. *Biochemical Journal* **417**(1):1–13. DOI 10.1042/BJ20081386.

Münch C, Harper JW. 2016. Mitochondrial unfolded protein response controls matrix pre-rna processing and translation. *Nature* **534**(7609):710–713. DOI 10.1038/nature18302.

Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, Youle RJ. 2010. Pink1 is selectively stabilized on impaired mitochondria to activate parkin. *PLOS Biology* **8**(1):e1000298. DOI 10.1371/journal.pbio.1000298.

Narendra D, Tanaka A, Suen DF, Youle RJ. 2008. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *Journal of Cell Biology* **183**(5):795–803. DOI 10.1083/jcb.200809125.

Narendra D, Walker JE, Youle R. 2012. Mitochondrial quality control mediated by pink1 and parkin: links to parkinsonism. *Cold Spring Harbor Perspectives in Biology* **4**(11):a011338. DOI 10.1101/cshperspect.a011338.
Nargund AM, Pellegrino MW, Fiorese CJ, Baker BM, Haynes CM. 2012. Mitochondrial import efficiency of ATFS-1 regulates mitochondrial upr activation. *Science* **337**(6094):587–590 DOI 10.1126/science.1223560.

Neupert W, Herrmann JM. 2007. Translocation of proteins into mitochondria. *Annual Review of Biochemistry* **76**(1):723–749 DOI 10.1146/annurev.biochem.76.052705.163409.

Nimmo GAM, Venkatesh S, Pandey AK, Marshall CR, Hazrati LN, Blaser S, Ahmed S, Cameron J, Singh K, Ray PN, Suzuki CK, Yoon G. 2019. Bi-allelic mutations of Lonp1 encoding the mitochondrial Lonp1 protease cause pyruvate dehydrogenase deficiency and profound neurodegeneration with progressive cerebellar atrophy. *Human Molecular Genetics* **28**(2):290–306 DOI 10.1093/hmg/ddy351.

Nolden M, Ehses S, Koppen M, Bernacchia A, Rugarli EI, Langer T. 2005. The M-Aaa protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. *Cell* **123**(2):277–289 DOI 10.1016/j.cell.2005.08.003.

Nunnari J, Suomalainen A. 2012. Mitochondria: in sickness and in health. *Cell* **148**(6):1145–1159 DOI 10.1016/j.cell.2012.02.035.

Pareek G, Pallanck LJ. 2020. Inactivation of the mitochondrial protease AFG3L2 results in severely diminished respiratory chain activity and widespread defects in mitochondrial gene expression. *PLOS Genetics* **16**(10):e1009118 DOI 10.1371/journal.pgen.1009118.

Pareek G, Thomas RE, Pallanck LJ. 2018. Loss of the drosophila M-Aaa mitochondrial protease paraplegin results in mitochondrial dysfunction, shortened lifespan, and neuronal and muscular degeneration. *Cell Death & Disease* **9**(3):304 DOI 10.1038/s41419-018-0365-8.

Pareek G, Thomas RE, Vincow ES, Morris DR, Pallanck LJ. 2018. Lon protease inactivation in drosophila causes unfolded protein stress and inhibition of mitochondrial translation. *Cell Death Discov* **4**(1):51 DOI 10.1038/s41420-018-0110-1.

Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. 2006. Mitochondrial dysfunction in drosophila pink1 mutants is complemented by parkin. *Nature* **441**(7097):1157–1161 DOI 10.1038/nature04788.

Patron M, Sprenger HG, Langer T. 2018. M-Aaa proteases, mitochondrial calcium homeostasis and neurodegeneration. *Cell Research* **28**(3):296–306 DOI 10.1038/s41420-018-0107-1.

Pfanner N, Warscheid B, Wiedemann N. 2019. Mitochondrial proteins: from biogenesis to functional networks. *Nature Reviews Molecular Cell Biology* **20**(5):267–284 DOI 10.1038/s41580-018-0092-0.

Pfeffer G, Gorman GS, Griffin H, Kurzawa-Akanbi M, Blakely EL, Wilson I, Sitarz K, Moore D, Murphy JL, Alston CL, Pyle A, Coxhead J, Payne B, Gorrie GH, Longman C, Hadjivassiliou M, McConville J, Dick D, Imam I, Hilton D, Norwood F, Baker MR, Jaisser SR, Yu-Wai-Man P, Farrell M, McCarthy A, Lynch T, McFarland R, Schaefer AM, Turnbull DM, Horvath R, Taylor RW, Chinnery PF. 2014. Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. *Brain* **137**(Pt 5):1323–1336 DOI 10.1093/brain/awu060.

Picchioni D, Antolin-Fontes A, Camacho N, Schmitz C, Pons-Pons A, Rodríguez-Escribà M, Machallekídiou A, Güler MN, Siatra P, Carretero-Junquera M, Serrano A, Hovde SL, Knobel PA, Novoa EM, Solá-Vilarrubias M, Kaguni LS, Stracker TH, Ribas de Pouplana L. 2019. Mitochondrial protein synthesis and mtDNA levels coordinated through an aminocyl-tRNA synthetase subunit. *Cell Reports* **27**(1):40–47.e5 DOI 10.1016/j.celrep.2019.03.022.

Pickles S, Vigié P, Youle RJ. 2018. Mitophagy and quality control mechanisms in mitochondrial maintenance. *Current Biology* **28**(4):R170–R185 DOI 10.1016/j.cub.2018.01.004.
Pierson TM, Adams D, Bonn F, Martinelli P, Cherukuri PF, Teer JK, Hansen NF, Cruz P, Mullikin for the NISC Comparative Sequencing Program JC, Blakesley RW, Golas G, Kwan J, Sandler A, Fuentes Fajardo K, Markello T, Tifft C, Blackstone C, Rugarli EI, Langer T, Gahl WA, Toro C, Cox GA. 2011. Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial M-Aaa proteases. *PLOS Genetics* 7(10):e1002325 DOI 10.1371/journal.pgen.1002325.

Pollecker K, Sylvester M, Voos W. 2021. Proteomic analysis demonstrates the role of the quality control protease lonp1 in mitochondrial protein aggregation. *Journal of Biological Chemistry* 297(4):101134 DOI 10.1016/j.jbc.2021.101134.

Pomatto LCD, Carney C, Shen B, Wong S, Halaszynski K, Salomon MP, Davies KJA, Tower J. 2017. The mitochondrial lon protease is required for age-specific and sex-specific adaptation to oxidative stress. *Current Biology* 27(1):1–15 DOI 10.1016/j.cub.2016.10.044.

Potting C, Wilnes C, Engmann T, Osman C, Langer T. 2010. Regulation of mitochondrial phospholipids by Ups1/Preli-like proteins depends on proteolysis and Mdm35. *EMBO Journal* 29(17):2888–2898 DOI 10.1038/emboj.2010.169.

Pryde KR, Taanman JW, Schapira AH. 2016. A lon-clpp proteolytic axis degrades complex i to extinguish ros production in depolarized mitochondria. *Cell Reports* 17(10):2522–2531 DOI 10.1016/j.celrep.2016.11.027.

Puchades C, Ding B, Song A, Wiseman RL, Lander GC, Glynn SE. 2019. Unique Structural features of the mitochondrial AAA+ protease AFG3L2 Reveal the molecular basis for activity in health and disease. *Molecular Cell* 75(5):1073–85.e6 DOI 10.1016/j.molcel.2019.06.016.

Puchades C, Rampello AJ, Shin M, Giuliani CJ, Wiseman RL, Glynn SE, Lander GC. 2017. Structure of the mitochondrial inner membrane AAA+ protease yme1 gives insight into substrate processing. *Science* 358(6363):eaao0464 DOI 10.1126/science.aao0464.

Qi Y, Liu H, Daniels MP, Zhang G, Xu H. 2016. Loss of drosophila I-Aaa protease, Dyme1l, causes abnormal mitochondria and apoptotic degeneration. *Cell Death and Differentiation* 23(2):291–302 DOI 10.1038/cdd.2015.94.

Quiles JM, Gustafsson AB. 2020. Mitochondrial quality control and cellular proteostasis: two sides of the same coin. *Frontiers in Physiology* 11:515 DOI 10.3389/fphys.2020.00515.

Quinlan CL, Perevoschikova IV, Hey-Mogensen M, Orr AL, Brand MD. 2013. Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. *Redox Biology* 1(1):304–312 DOI 10.1016/j.redox.2013.04.005.

Quirós P M, Español Y, Acín-Pérez R, Rodríguez F, Bárzaba C, Watanabe K, Calvo E, Loureiro M, Fernández-García MS, Fuego A, Vázquez J, Enríquez JA, López-Otín C. 2014. Atp-dependent lon protease controls tumor bioenergetics by reprogramming mitochondrial activity. *Cell Reports* 8(2):542–556 DOI 10.1016/j.celrep.2014.06.018.

Quirós PM, Langer T, López-Otín C. 2015. New roles for mitochondrial proteases in health, ageing and disease. *Nature Reviews Molecular Cell Biology* 16(6):345–359 DOI 10.1038/nrm3984.

Rainbolt TK, Atanassova N, Genereux JC, Wiseman RL. 2013. Stress-regulated translational attenuation adapts mitochondrial protein import through Tim17a degradation. *Cell Metabolism* 18(6):908–919 DOI 10.1016/j.cmet.2013.11.006.

Rainbolt TK, Lebeau J, Puchades C, Wiseman RL. 2016. Reciprocal degradation of Yme1l and oma1 adapts mitochondrial proteolytic activity during stress. *Cell Reports* 14(9):2041–2049 DOI 10.1016/j.celrep.2016.02.011.
Rainbolt TK, Saunders JM, Wiseman RL. 2015. Yme1l degradation reduces mitochondrial proteolytic capacity during oxidative stress. EMBO Reports 16(1):97–106 DOI 10.15252/embr.201438976.

Rampello AJ, Glynn SE. 2017. Identification of a degradation signal sequence within substrates of the mitochondrial I-Aaa protease. Journal of Molecular Biology 429(6):873–885 DOI 10.1016/j.jmb.2017.02.009.

Rivadeneira DB, Caino MC, Seo JH, Angelin A, Wallace DC, Languino LR, Altieri DC. 2015. Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Science Signaling 8(389):ra80 DOI 10.1126/scisignal.aab1624.

Roca-Portoles A, Tait SWG. 2021. Mitochondrial quality control: from molecule to organelle. Cellular and Molecular Life Sciences 78(8):3853–3866 DOI 10.1007/s00018-021-03775-0.

Ross CA, Poirier MA. 2004. Protein aggregation and neurodegenerative disease. Nature Medicine 10 Suppl:S10–7 DOI 10.1038/nm1066.

Ruan L, Wang Y, Zhang X, Tomaszewski A, McNamara JT, Li R. 2020. Mitochondria-associated proteostasis. Annual Review of Biophysics 49(1):41–67 DOI 10.1146/annurev-biophys-121219-081604.

Ruan L, Zhou C, Jin E, Kucharavy A, Zhang Y, Wen Z, Florens L, Li R. 2017. Cytosolic proteostasis through importing of misfolded proteins into mitochondria. Nature 543(7645):443–446 DOI 10.1038/nature21695.

Rugarli EI, Langer T. 2012. Mitochondrial quality control: a matter of life and death for neurons. The EMBO Journal 31(6):1336–1349 DOI 10.1038/emboj.2012.38.

Rumyantseva A, Popovic M, Trifunovic A. 2022. Clpp deficiency ameliorates neurodegeneration caused by impaired mitochondrial protein synthesis. Brain 145(1):92–104 DOI 10.1093/brain/awab303.

Sancak Y, Markhard AL, Kitami T, Kovács-Bogdán E, Kamer KJ, Udeshi ND, Carr SA, Chaudhuri D, Clapham DE, Li AA, Calvo SE, Goldberger O, Mootha VK. 2013. Emre is an essential component of the mitochondrial calcium uniporter complex. Science 342(6164):1379–1382 DOI 10.1126/science.1242993.

Sauer RT, Baker TA. 2011. Aaa+ proteases: atp-fueled machines of protein destruction. Annual Review of Biochemistry 80(1):587–612 DOI 10.1146/annurev-biochem-060408-172623.

Sauer RT, Bolon DN, Burton BM, Burton RE, Flynn JM, Grant RA, Hersch GL, Joshi SA, Kenniston JA, Levchenko I, Neher SB, Oakes ES, Siddiqui SM, Wah DA, Baker TA. 2004. Sculpting the proteome with aaa(+) proteases and disassembly machines. Cell 119(1):9–18 DOI 10.1016/j.cell.2004.09.020.

Scarffe LA, Stevens DA, Dawson VL, Dawson TM. 2014. Parkin and pink1: much more than mitophagy. Trends in Neurosciences 37(6):315–324 DOI 10.1016/j.tins.2014.03.004.

Seiferling D, Szczepanowska K, Becker C, Senft K, Hermans S, Maiti P, König T, Kukat A, Trifunovic A. 2016. Loss of CLPP alleviates mitochondrial cardiomyopathy without affecting the mammalian Uprmt. EMBO Reports 17(7):953–964 DOI 10.15252/embr.201642077.

Seo JH, Rivadeneira DB, Caino MC, Chae YC, Speicher DW, Tang HY, Vaira V, Bosari S, Palleschi A, Rampini P, Kossenkov AV, Languino LR, Altieri DC. 2016. The mitochondrial unfoldase-peptidase complex clpXP controls bioenergetics stress and metastasis. PLOS Biology 14(7):e1002507 DOI 10.1371/journal.pbio.1002507.

Shi H, Rampello AJ, Glynn SE. 2016. Engineered Aaa+ proteases reveal principles of proteolysis at the mitochondrial inner membrane. Nature Communications 7(1):13301 DOI 10.1038/ncomms13301.
Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM. 2011. Paris (Znf746) repression of pgc-1α contributes to neurodegeneration in parkinson’s disease. Cell 144(5):689–702 DOI 10.1016/j.cell.2011.02.010.

Shin M, Watson ER, Song AS, Mindrebo JT, Novick SJ, Griffin PR, Wiseman RL, Lander GC. 2021. Structures of the human lonp1 protease reveal regulatory steps involved in protease activation. Nature Communications 12(1):3239 DOI 10.1038/s41467-021-23495-0.

Song JY, Marszalek J, Craig EA. 2012. Cysteine desulfurase Nfs1 and Pim1 Protease control levels of isu, the Fe-S cluster biogenesis scaffold. Proceedings of the National Academy of Sciences of the United States of America 109(26):10370–10375 DOI 10.1073/pnas.1206945109.

Sousa JS, D’Imprima E, Vonck J. 2018. Mitochondrial respiratory chain complexes. Subcell Biochem 87:167–227 DOI 10.1007/978-981-10-7757-9.

Sprenger HG, Wani G, Hesseling A, König T, Patron M, MacVicar T, Ahola S, Wai T, Barth E, Rugarli EI, Bergami M, Langer T. 2019. Loss of the mitochondrial I-Aaa protease Yme1l leads to ocular dysfunction and spinal axonopathy. EMBO Molecular Medicine 11(1):e9288 DOI 10.15252/emmm.201809288.

Steele TE, Glynn SE. 2019. Mitochondrial aaa proteases: a stairway to degradation. Mitochondrion 49(6):121–127 DOI 10.1016/j.mito.2019.07.012.

Strauss KA, Jinks RN, Puffenberger EG, Venkatesh S, Singh K, Cheng I, Mikita N, Thilagavathi J, Lee J, Sarafianos S, Benkert A, Koehler A, Zhu A, Trovillion V, McGlincy M, Morlet T, Deardorff M, Innes AM, Prasad C, Chudley AE, Lee IN, Suzuki CK. 2015. Codas syndrome is associated with mutations of lonp1, encoding mitochondrial Aaa+ lon protease. American Journal of Human Genetics 96(1):121–135 DOI 10.1016/j.ajhg.2014.12.003.

Sun N, Malide D, Liu J, Rovira II, Combs CA, Finkel T. 2017. A fluorescence-based imaging method to measure in vitro and in vivo mitophagy using mt-keima. Nature Protocols 12(8):1576–1587 DOI 10.1038/nprot.2017.060.

Sung YJ, Kao TY, Kuo CI, Fan CC, Cheng AN, Fang WC, Chou HY, Lo YK, Chen CH, Jiang SS, Chang IS, Hsu CH, Lee JC, Lee AY. 2018. Mitochondrial lon sequesters and stabilizes P53 in the matrix to restrain apoptosis under oxidative stress via its chaperone activity. Cell Death & Disease 9(6):697 DOI 10.1038/s41419-018-0730-7.

Szczepanowska K, Maiti P, Kukat A, Hofsetz E, Nolte H, Senft K, Becker C, Ruzzenente B, Hornig-Do HT, Wibom R, Wiesner RJ, Krüger M, Trifunovic A. 2016. Clpp coordinates mitoribosomal assembly through the regulation of eral1 levels. Embo Journal 35(23):2566–2583 DOI 10.15252/embj.201694253.

Tamura Y, Endo T, Iijima M, Sesaki H. 2009. Ups1p and Ups2p antagonistically regulate cardiolipin metabolism in mitochondria. Journal of Cell Biology 185(6):1029–1045 DOI 10.1083/jcb.200812018.

Taouktsi E, Kyriakou E, Smyrniotis S, Borbolis F, Bondi L, Avgeris S, Trigazis E, Rigas S, Voutsinas GE, Syntichaki P. 2022. Organismal and cellular stress responses upon disruption of mitochondrial Lonp1 protease. Cells 11(8):1363 DOI 10.3390/cells11081363.

Thomas RE, Andrews LA, Burman JL, Lin WY, Pallanck LJ. 2014. Pink1-parkin pathway activity is regulated by degradation of Pink1 in the mitochondrial matrix. PLOS Genetics 10(5):e1004279 DOI 10.1371/journal.pgen.1004279.

Torres-Odio S, Lei Y, Gispert S, Maletzko A, Key J, Menissy SS, Wittig I, Auburger G, West AP. 2021. Loss of mitochondrial protease clpp activates type i ifn responses through the mitochondrial DNA-Cgas-sting signaling axis. Journal of Immunology 206(8):1890–1900 DOI 10.4049/jimmunol.2001016.
Tsai CW, Wu Y, Pao PC, Phillips CB, Williams C, Miller C, Ranaghan M, Tsai MF. 2017. Proteolytic control of the mitochondrial calcium uniporter complex. Proceedings of the National Academy of Sciences of the United States of America 114(17):4388–4393 DOI 10.1073/pnas.1702938114.

Vasan K, Werner M, Chandel NS. 2020. Mitochondrial metabolism as a target for cancer therapy. Cell Metabolism 32(3):341–352 DOI 10.1016/j.cmet.2020.06.019.

Vicario M, Cieri D, Brini M, Calì T. 2018. The close encounter between alpha-synuclein and mitochondria. Frontiers in Neuroscience 12:388 DOI 10.3389/fnins.2018.00388.

Vincow ES, Merrihew G, Thomas RE, Shulman NJ, Beyer RP, MacCoss MJ, Pallanck LJ. 2013. The pink1-parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proceedings of the National Academy of Sciences of the United States of America 110(16):6400–6405 DOI 10.1073/pnas.1221132110.

Vincow ES, Thomas RE, Merrihew GE, Shulman NJ, Bammler TK, MacDonald JW, MacCoss MJ, Pallanck LJ. 2019. Autophagy accounts for approximately one-third of mitochondrial protein turnover and is protein selective. Autophagy 15(9):1592–1605 DOI 10.1080/15548627.2019.1586258.

Whitworth AJ, Pallanck LJ. 2017. Pink1/Parkin mitophagy and neurodegeneration—what do we really know in vivo? Current Opinion in Genetics & Development 44:47–53 DOI 10.1016/j.gde.2017.01.016.

Wilkinson PA, Crosby AH, Turner C, Bradley LJ, Ginsberg L, Wood NW, Schapira AH, Warner TT. 2004. A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. Brain 127(Pt 5):973–980 DOI 10.1093/brain/awh125.

Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H, Lu B. 2006. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of drosophila pink1 is rescued by parkin. Proceedings of the National Academy of Sciences of the United States of America 103(28):10793–10798 DOI 10.1073/pnas.0602493103.

Yien YY, Ducamp S, van der Vorm LN, Kardon JR, Manceau H, Kannengiesser C, Bergonia HA, Kafina MD, Karim Z, Gouya I, Baker TA, Puy H, Phillips JD, Nicolas G, Paw BH. 2017. Mutation in human clpx elevates levels of δ-aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. Proceedings of the National Academy of Sciences of the United States of America 114(38):E8045–e52 DOI 10.1073/pnas.1700632114.

Youle RJ. 2019. Mitochondria-striking a balance between host and endosymbiont. Science 365(6454):1 DOI 10.1126/science.aaw9855.
Youle RJ, van der Bliek AM. 2012. Mitochondrial fission, fusion, and stress. Science 337(6098):1062–1065 DOI 10.1126/science.1219855.

Zhao RZ, Jiang S, Zhang L, Yu ZB. 2019. Mitochondrial electron transport chain, ros generation and uncoupling (Review). International Journal of Molecular Medicine 44(1):3–15 DOI 10.3892/ijmm.2019.4188.

Zurita Rendón O, Shoubridge EA. 2018. Lonp1 is required for maturation of a subset of mitochondrial proteins, and its loss elicits an integrated stress response. Molecular and Cellular Biology 38(20):e00412–e00417 DOI 10.1128/MCB.00412-17.